HCM
DMAAR

Heights Capital Management’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Heights Capital Management’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-234,109
Closed -$37K – 289
2025
Q4 		$37K Sell
234,109
-55,193
-19% -$10.7K 0.01% 144
2025
Q3 		$62.9K Sell
289,302
-344,514
-54% -$64K 0.02% 123
2025
Q2 		$79.2K Buy
+633,816
New +$81.5K 0.02% 103

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Heights Capital Management's DMAAR Position: Q1 2026 in Review

Heights Capital Management sold out of Drugs Made In America Acquisition Corp Rights (DMAAR) in Q1 2026, closing a stake of 234,109 shares — an estimated $37K sold.

Heights Capital Management first reported a position in DMAAR in Q2 2025 and held it in 3 quarters. The position peaked at $79.2K in Q2 2025. 35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

  • Heights Capital Management reported no remaining Drugs Made In America Acquisition Corp Rights position as of Q1 2026 after selling out during the quarter.
  • Heights Capital Management sold 234,109 Drugs Made In America Acquisition Corp Rights shares in Q1 2026, an estimated $37K.
  • Heights Capital Management first reported a position in Drugs Made In America Acquisition Corp Rights in Q2 2025 and held it in 3 quarters.
  • Heights Capital Management's Drugs Made In America Acquisition Corp Rights position peaked at $79.2K in Q2 2025.
  • 35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on Heights Capital Management's 13F filing for Q1 2026, filed 15 May 2026.